Immunity

Ecuador: raid on Mexican embassy draws international criticism – but President Noboa hopes voters approve

Retrieved on: 
Wednesday, April 10, 2024

Ecuador’s security forces recently conducted a raid on the Mexican embassy in the country’s capital city, Quito.

Key Points: 
  • Ecuador’s security forces recently conducted a raid on the Mexican embassy in the country’s capital city, Quito.
  • Against the backdrop of rampant narco-terrorism and escalating regional tensions, concerns have been raised about Ecuador’s respect for these fundamental principles.
  • The police raid on April 5 has drawn widespread criticism targeting Ecuador’s president, Daniel Noboa.
  • The country’s president, Andrés Manuel López Obrador, condemned what it called the “despicable authoritarian” raid which is declared to be in violation of international law.

A political raid

  • To an extent the raid on the Mexican embassy is bound up with the Ecuadorian government’s aggressive approach to the country’s problems with drugs and gang violence.
  • Noboa’s initially high approval ratings have been falling thanks to the public perception that his hardline policies have done little to address the issue.
  • But Noboa’s referendum appears to serve a dual political purpose.

Sovereignty and security

  • So the raid on the Mexican embassy has raised doubts in many people’s minds as to whether a government with apparently scant regard for international law can be trusted not to abuse its new security laws.
  • The importance of Mexico’s relationship with Ecuador is central to addressing the mobility crisis in the region.
  • To protect people’s security in the region, diplomatic collaboration between countries such as Ecuador and Mexico is vital.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

One-Two Punch of Wireless and PLC Set to Transform IIoT

Retrieved on: 
Tuesday, April 9, 2024

Reliable communication is a critical piece of industrial systems becoming "smart," as it facilitates remote monitoring and management capabilities.

Key Points: 
  • Reliable communication is a critical piece of industrial systems becoming "smart," as it facilitates remote monitoring and management capabilities.
  • Making this all possible is the marriage of two powerful communication technologies: Power Line Communication (PLC) and wireless mesh networks.
  • Together, they create a hybrid network that combines the reliability of PLC with the accessibility of wireless, forming the backbone of a robust IIoT ecosystem.
  • As technology continues to evolve, the adoption of PLC and wireless hybrid networks is expected to grow, unlocking new possibilities and driving innovation across industries.

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Retrieved on: 
Monday, April 8, 2024

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.

Key Points: 
  • The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
  • It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
  • “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024

The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.

Key Points: 
  • The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
  • “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads.
  • In the studies presented at AACR, scientists at Calidi Biotherapeutics and City of Hope researched the stem cells secretome transcriptomic of CLD-101 and CLD-201.
  • This poster will be posted to the “Scientific Publications” section of the Calidi Biotherapeutics website following the conclusion of the conference.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

Key Points: 
  • Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs.
  • This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.
  • The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
  • Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
Thursday, March 21, 2024

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

Supreme Court Hears Oral Argument in Pivotal NCLA Case Against Gov’t Social Media Censorship

Retrieved on: 
Monday, March 18, 2024

The vast, coordinated silencing of First Amendment-protected speech has targeted influential, highly qualified voices including doctors and scientists like Drs.

Key Points: 
  • The vast, coordinated silencing of First Amendment-protected speech has targeted influential, highly qualified voices including doctors and scientists like Drs.
  • We went to social media to voice our opinions and were silenced by government employees who bullied social media snowflakes into silencing our voices.
  • In the Murthy v. Missouri case, the Supreme Court has the opportunity to restore the First Amendment in this country.
  • That is what the government did here, and if that is allowed then the First Amendment is a dead letter.”

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

Retrieved on: 
Thursday, March 14, 2024

Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.

Key Points: 
  • Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.
  • Dr. Hariri has led the effort to harness the unique biology of placental-derived cells in a range of clinical indications, including cancer, autoimmune and degenerative diseases.
  • “Dr.
  • This work puts Dr. Hariri at the forefront of the longevity movement, with his finger on the pulse of the ever-changing landscape.”
    The ABUNDANCE Summit will occur in Los Angeles, Calif., from March 17 through 21, 2024.

IMUNON Files IND Application to Begin Human Testing of IMNN-101

Retrieved on: 
Wednesday, March 13, 2024

LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for IMNN-101 for a Phase 1 clinical study with a seasonal COVID-19 booster vaccine. Following acceptance by the FDA, enrollment in this human proof-of-concept study is expected to begin in the second quarter of 2024.

Key Points: 
  • Following acceptance by the FDA, enrollment in this human proof-of-concept study is expected to begin in the second quarter of 2024.
  • The primary objectives of the Phase 1 study are to evaluate the vaccine safety, tolerability and neutralizing antibody response and its durability in healthy adults.
  • “We are delighted to have completed the work necessary to file this IND application and look forward to demonstrating proof-of-concept for our PlaCCine platform in COVID-19.
  • We’re looking forward to generating the proof-of-concept data necessary to begin these dialogues,” Mr. Tardugno added.